Exact Sciences has launched the next-generation sequencing (NGS) OncoExTra cancer therapy selection genomic test in the US.

The comprehensive DNA and RNA-based test has been designed to provide a complete molecular picture of a patient’s cancer to doctors and users.

OncoExTra provides each patient with personalised and actionable results.

Exact Sciences chairman and CEO Kevin Conroy said: “Exact Sciences continues to build its leadership in cancer diagnostics by offering innovative tests addressing clinical needs at every step of patient cancer care.

“We are proud to add OncoExTra to our growing portfolio of cancer solutions across the cancer-care continuum, and deliver new levels of tumour-specific information and insights to doctors and patients that guide vital treatment decisions to achieve the best outcomes.”

Using NGS, the OncoExTra test evaluates the RNA and DNA of a tumour to provide actionable information that can guide treatment decisions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

It profiles the complete exome as well as transcriptome across nearly 20,000 genes. It also analyses all genes recommended by the National Comprehensive Cancer Network (NCCN) for solid tumour patients and provides intuitive reports.

With the help of matched tumour-normal sequencing, the test also restricts false positives and allows physicians to make clinical decisions based on identified somatic variants.

The OncoExTra test also provides information related to targetable mutations and fusions, immuno-oncology signatures, and clinical trial options.

The selection of treatments for advanced, metastatic, refractory, relapsed or recurrent cancer patients is facilitated by the test’s comprehensive tumour profiling, which leverages whole exome and transcriptome sequencing.

It has an extensive test of around 20,000 genes and 169 introns.